After the six Industrial Dialogues that took place in 2017, some of the tools have been tested during the SMART-map pilot phase.
The aim of the pilots is to evaluate if the RRI tools, co-designed and co-developed with societal actors during the early stages of the project, can be effectively and implemented within the innovation pipeline of real companies. Three industrial actors, one for each innovation topic, have been involved in this phase of the project.
The SMART Map for Precision Medicine is being tested in Spain, at IMEGEN, a biomedical biotechnological company based in Valencia, that is also a partner of the project.
The SMART Map for 3D Printing in Biomedicine is being evaluated within the context of SYMBIONICA project (Reconfigurable Machine for the new Additive and Subtractive Manufacturing of next generation fully personalized bionics and smart prosthetics), a Research and Innovation Action granted by the European Commission under the Horizon 2020 Programme. One of the milestones of the 3Dmed pilot phase is the multi-stakeholder workshop, a tool aiming at starting a multi-actor discussion on new rules for 3D printing process in biomedicine. The workshop took place in Milan on 20-21 March and was an occasion to discuss regulatory options to foster the full flourishing of this new technology in biomedicine in line with needs and expectation of patients and societal actors.
The SMART Map for Synthetic Biology, being tested in the UK, is “A Repository of Learning Case Studies”. The overall aim is to help and support industry practitioners learn from their own experiences and that of others to understand what it means to institutionalise Responsible Research and Innovation. The objective of the first phase was to produce a small number of examples as input to an eventual repository of short cases. Several organisations agreed to write the case studies, including actors from small biotech, civil society organisation, the public sector and “knowledge intermediary”.